Asston Pharmaceuticals SME IPO Subscription Status
Asston Pharmaceuticals SME IPO closed on 11 July 2025 with an overall subscription of 186.55x based on shares applied. QIB demand came in at 85.76x, NII at 352.97x, and retail at 170.50x.
Allotment will be finalised on 14 July 2025. The stock is scheduled to list on NSE and BSE on 16 July 2025.
Issue Price
Rs 123.00
GMP Today
Rs 26.00 (+21.14%)
Overall Subscription
186.55x
Issue Size
₹26.17 Cr
Allotment Date
14 Jul 2025
Listing Date
16 Jul 2025
Asston Pharmaceuticals SME IPO Subscription by Amount
Category-wise subscription based on amount applied at issue price Rs 123.00
| Category | Amount Offered | Amount Applied | Subscription |
|---|---|---|---|
| QIB | Rs 5.23 Cr | Rs 448.32 Cr | 85.76x |
| NII | Rs 3.96 Cr | Rs 1,397.98 Cr | 352.97x |
| sNII (Rs 2L to Rs 10L) | Rs 1.32 Cr | Rs 276.85 Cr | 210.36x |
| bNII (above Rs 10L) | Rs 2.64 Cr | Rs 1,122.52 Cr | 424.47x |
| IND | Rs 9.18 Cr | Rs 1,564.49 Cr | 170.50x |
| Total | Rs 18.36 Cr | Rs 3,410.79 Cr | 185.73x |
Asston Pharmaceuticals SME IPO Subscription by Shares
Category-wise subscription based on shares bid. Application-wise bid counts are not available for this IPO yet.
| Category | Shares Offered | Shares Bid | Subscription |
|---|---|---|---|
| QIB | 4,25,000 | 3,64,49,000 | 85.76x |
| NII | 3,22,000 | 11,36,57,000 | 352.97x |
| sNII (Rs 2L to Rs 10L) | 1,07,000 | 2,25,08,000 | 210.36x |
| bNII (above Rs 10L) | 2,15,000 | 9,12,62,000 | 424.47x |
| IND | 7,46,000 | 12,71,94,000 | 170.50x |
| Total | 14,93,000 | 27,73,00,000 | 185.73x |
What Do These Subscription Numbers Mean?
A subscription of 186.55x by shares means the IPO received bids for 187 times the shares reserved. Allotment odds depend on application count in each category, not share volume.
Here is what each category number tells you:
QIB at 85.76x by shares: This is the strongest signal on the page. QIBs are institutional investors, mutual funds, foreign institutions, and banks. When they subscribe at 85.76x, it reflects serious institutional conviction.
NII at 352.97x by shares: NII includes high net worth individuals applying above Rs 2 lakh. Proportional allotment uses application subscription.
Retail at 170.50x by shares: Allotment is by lottery, but application-wise data is needed for accurate 1-in-X odds. Share oversubscription often overstates how hard allotment is.
Asston Pharmaceuticals SME IPO Allotment Chances
Allotment odds below use application subscription (number of bids received), not share or amount subscribed.
Retail (IND)
- •Share subscription: 170.50x (application-wise data pending).
- •Allotment odds will be updated once application subscription is synced.
SHNI (Rs 2 lakh to Rs 10 lakh)
- •Share subscription: 210.36x (application-wise data pending).
- •Allotment odds will be updated once application subscription is synced.
BHNI (above Rs 10 lakh)
- •Share subscription: 424.47x (application-wise data pending).
- •Allotment odds will be updated once application subscription is synced.
Check the Asston Pharmaceuticals SME IPO Allotment Status page from 14 July 2025 for your allotment result.
Asston Pharmaceuticals SME IPO GMP After Subscription
GMP for Asston Pharmaceuticals SME stands at Rs 26.00 today, giving an estimated listing price of Rs 149.00 per share.
The GMP has moved up from Rs 10.00 on 4 Jul 2025 to Rs 22.00 on 14 Jul 2025.
A subscription of 186.55x combined with a GMP of 21.14% is a strong combination heading into listing. QIB demand above 50x in particular tends to support listing sentiment, as institutional investors are seen as informed buyers.
Track live GMP on the Asston Pharmaceuticals SME IPO GMP Today page or the IPOwiz Live IPO GMP Tracker.
Asston Pharmaceuticals SME IPO Day-wise Subscription
| Day | QIB | NII | Retail | Overall |
|---|---|---|---|---|
| Day 1 - 9 Jul 2025 | 3.51x | 0.66x | 1.22x | 1.75x |
| Day 2 - 10 Jul 2025 | 4.47x | 19.67x | 16.66x | 13.84x |
| Day 3 - 11 Jul 2025 | 85.76x | 352.97x | 170.50x | 185.73x |
Asston Pharmaceuticals SME IPO Key Dates
| Event | Date |
|---|---|
| IPO Open Date | 9 July 2025 |
| IPO Close Date | 11 July 2025 |
| Allotment Date | 14 July 2025 |
| Refund Initiation | 15 July 2025 |
| Share Credit to Demat | 15 July 2025 |
| Listing Date | 16 July 2025 |
| Minimum Investment | Rs 2,46,000.00 |
| Lot Size | 1000 shares |
About Asston Pharmaceuticals SME
No company information available
Understanding Subscription Categories
QIB - Qualified Institutional Buyers
Includes foreign institutional investors, domestic financial institutions, mutual funds, and other qualified institutions. QIB demand is considered the most reliable indicator of institutional confidence in an IPO.
NII - Non-Institutional Investors
High net worth individuals applying above Rs 2 lakh. Divided into bNII (above Rs 10 lakh) and sNII (Rs 2 lakh to Rs 10 lakh). NII allotment is proportional.
IND - Individual Investors
Investors applying up to Rs 2 lakh per PAN. Allotment is by lottery when oversubscribed. Minimum one lot per successful applicant.
Asston Pharmaceuticals SME IPO GMP Today
Live GMP, listing price estimate, and listing gain
Asston Pharmaceuticals SME IPO Allotment Status
Check allotment result on allotment date
Asston Pharmaceuticals SME IPO Details
Financials, peers, strengths, and review
All IPO Subscription Status
Subscription for all active IPOs
Asston Pharmaceuticals SME IPO Subscription FAQs
What is Asston Pharmaceuticals SME IPO subscription status today?
Asston Pharmaceuticals SME IPO subscription closed on 11 July 2025 with overall subscription of 186.55x (by shares) as of 27 June 2026, 2:01 AM IST. QIB 85.76x, NII 352.97x, IND 170.50x.
What is the overall subscription of Asston Pharmaceuticals SME IPO?
Asston Pharmaceuticals SME IPO is subscribed 186.55x overall by shares at close on 11 July 2025. QIB 85.76x, NII 352.97x, and IND 170.50x.
What is Asston Pharmaceuticals SME IPO QIB subscription?
Asston Pharmaceuticals SME IPO QIB (Qualified Institutional Buyers) subscription is 85.76x by shares. QIB includes mutual funds, FIIs, banks, and other institutions.
What is Asston Pharmaceuticals SME IPO IND subscription?
Asston Pharmaceuticals SME IPO IND subscription is 170.50x by shares. Minimum retail bid is up to Rs 2 lakh per PAN.
What is Asston Pharmaceuticals SME IPO NII subscription?
Asston Pharmaceuticals SME IPO NII (Non-Institutional Investors) subscription is 352.97x by shares. NII covers bids above Rs 2 lakh.
What are allotment chances in Asston Pharmaceuticals SME IPO for retail?
Asston Pharmaceuticals SME IPO retail share subscription is 170.50x. Application-wise data is needed for accurate lottery odds.
When is Asston Pharmaceuticals SME IPO allotment date?
Asston Pharmaceuticals SME IPO allotment date is 14 July 2025. Check Asston Pharmaceuticals SME IPO Allotment Status on IPOwiz from that day using your PAN.
When does Asston Pharmaceuticals SME IPO subscription close?
Asston Pharmaceuticals SME IPO subscription closed on 11 July 2025. No new applications are accepted after the close.
What is Asston Pharmaceuticals SME IPO GMP today?
Asston Pharmaceuticals SME IPO GMP is ₹26 today (+21.14% over issue price ₹123). See live GMP on the Asston Pharmaceuticals SME IPO GMP Today page.
What is Asston Pharmaceuticals SME IPO issue price and lot size?
Asston Pharmaceuticals SME IPO issue price is ₹123 per share. Lot size is 1000 shares. Minimum investment is ₹2,46,000 per lot (minimum 2 lots for SME). Issue size: ₹26.17 Cr.
When is Asston Pharmaceuticals SME IPO listing date?
Asston Pharmaceuticals SME IPO listing date is 16 July 2025 on NSE and BSE. Allotment is on 14 July 2025.
How does subscription affect Asston Pharmaceuticals SME IPO allotment?
Allotment odds in Asston Pharmaceuticals SME IPO depend on application subscription in each category, not share volume. Retail uses lottery when oversubscribed. NII uses proportional allotment by applications. At 186.55x overall, competition is very high.
For allotment results from 14 July 2025, visit the Asston Pharmaceuticals SME IPO Allotment Status page. For listing day updates on 16 July 2025, download the IPOwiz App.
Reviewed by Dinesh Agrawal
15+ years in Indian capital markets and IPO research. Subscription data verified before publish.